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Abstract 
Objective​: Reproducibility is a core tenet of scientific research. A reproducible study is one 
where the results can be recreated by different investigators in different circumstances using the 
same methodology and materials. Unfortunately, reproducibility is not a standard to which the 
majority of research is currently adherent.  
Methods​: We objectively evaluated 300 trials in the field of Obstetrics and Gynecology for 
fourteen indicators of reproducibility. These indicators include availability of data, analysis 
scripts, pre-registration information, study protocols and whether or not the study was available 
via Open Access. We also assessed the trials for financial conflict of interest statements and 
source of funding. 
Results​: Of the 300 trials in our sample, 208 contained empirical data that could be assessed for 
reproducibility. None of the trials in our sample provided a link to their protocols or provided a 
statement on availability of materials. None were replication studies. Just 10.58% provided a 
statement regarding their data availability, while only 5.82% provided a statement on 
preregistration. 25.85% failed to report the presence or absence of conflicts of interest and 
54.08% did not state the origin of their funding. 
Conclusion​: Research in the field of Obstetrics and Gynecology is not consistently reproducible 
and frequently lacks conflict of interest disclosure. Consequences of this could be far-reaching 
and include increased research waste, widespread acceptance of misleading results and erroneous 
conclusions guiding clinical decision-making. 
Introduction 
Reproducibility in scientific literature refers to the ability of a third party researcher to replicate 
results of an original study, using the same materials and methodology.​1​ Reproducibility is one 
of the core tenets of scientific research, important so that authors can repeat experiments done by 
others and gain additional information to support or contradict the original results.​2 
Unfortunately, due to the race to publication and the pressures to be the first to reveal new 
findings, reproducibility and study repetition has fallen by the wayside.​3​ Inability to reproduce 
results can increase research waste, lead to widespread acceptance of misleading results and 
allow for erroneous conclusions to find their way into clinical decision-making.​4  
Oseltamivir, marketed under the trade name of Tamiflu, was first sold by Roche in 1999 and was 
purchased in the magnitude of tens of millions of doses during the H1N1 scare of 2009.​5​ It 
wasn’t until 2014 that the Cochrane Collaboration was able to reproduce and publish a review of 
all of the data that Roche gathered from clinical trials conducted in the early 2000s.​6,7​ Cochrane’s 
review found that the drug only decreased duration of symptoms from 7 days to 6.3 days, with 
no decrease in the number of hospitalizations or serious complications.​8​ In this situation, a 
pharmaceutical company intentionally discouraged reproducibility, costing governments around 
the world billions of dollars.​5  
Our study seeks to objectively evaluate the reproducibility of a broad, random sample of 
literature in the field of Obstetrics and Gynecology. Specifically we look for the indicators of 
reproducibility outlined by Hardwicke et al, including availability of data, analysis scripts, 
pre-registration information, study protocols and whether the study was available via Open 
Access.​9​ A study of this type and magnitude has never been conducted on Obstetrics and 
Gynecology literature, but there is evidence that there is a need for it. In 2018, Holding et al. 
published research indicating that estrogen receptor-ɑ activation is consistently sustained,​10 
contradicting the extensively-cited studies from 2000 and 2003, which indicated that activation 
was cyclical.​11,12​ Holding reports that his team attempted to reproduce and build on the results of 
the original studies, but obtained an entirely unexpected result, one which could have 
far-reaching consequences for estrogen receptor treatments down the road.​3​ Holding doubts that 
his team was the first to fail to reproduce the original results, but raises questions about the 
reproducibility of research and the presence of study repetition in Obstetrics and Gynecology 
literature.​3​ We hope that our findings may serve as a baseline on which reproducibility can be 
measured and serve as a starting point for discussions on how to improve future research in the 
field. 
Methods 
This study is observational and utilizes a cross-sectional design. We utilized the methodology of 
Hardwicke et al.​9​ with modifications. We reported our study in accordance with guidelines for 
meta-epidemiological methodology research​13​. Pertinent materials are available on the Open 
Science Framework (​https://osf.io/n4yh5/​).  
 
Journal and Study Selection 
The National Library of Medicine catalog was used to search journals using the tag; for this 
project we searched twice with Obstetrics[ST] and Gynecology[ST]. This search was performed 
on May 29, 2019. Inclusion criteria included “English” and “MEDLINE indexed”. Any journals 
that overlapped between the search terms were only included once. We extracted the ISSN for 
the final list of journals. If the electronic ISSN was unavailable, the linking ISSN was used. 
These ISSN were used for our Pubmed search, which was performed on May 31, 2019. Our 
time-frame for publications was from January 1, 2014 to December 31, 2018. From this PubMed 
search, we randomly sampled 300 publications to extract data from (​https://osf.io/fkj4c/​).  
 
Data Extraction Training 
We held a training meeting to ensure inter-rater reliability for our two investigators (DR and SR). 
The training included an in-person session to introduce the study protocol and extraction form. 
Investigators extracted data from 3 example articles independently. The investigators then 
compared data and reconciled differences. The training session was posted online 
(​https://osf.io/tf7nw/​). Finally, investigators extracted data from the first 10 articles on the list 
and held a brief consensus meeting to answer any final questions and reconcile any additional 
differences. Investigators then proceeded to extract data on the remaining 294 articles. Following 
all data extraction, a final consensus meeting was held to resolve any remaining differences. AB 
was available as a third author to resolve persistent disagreements, if any. 
 Data Extraction 
Data extraction was conducted in duplicate and blinded fashion. AB was available as a third 
author to resolve persistent disagreements, but was not required. Additions were made to the 
Google Form provided by Hardwicke et al. and the form was pilot-tested. ​9​ The form was 
designed so that coders could identify if a given study contained the information necessary to be 
reproducible. (​https://osf.io/3nfa5/​). The literature we searched was highly variable, including 
study designs that were excluded due to lack of empirical data (e.g., editorials, simulations, 
letters, etc.). Where available, we elected to include the 5-year impact factor and the impact 
factor for the most recent year. We included the following study designs: Meta-analyses, 
commentaries with re-analysis, cost-effectiveness studies, clinical trials, case studies, case 
control studies, data surveys, laboratory studies, multiple study types, cohort studies, case series, 
secondary analyses, chart reviews, and cross-sectional studies. Funding options included public, 
private, university, hospital, non-profit, no statement, no funding and mixed. 
 
Open Access Availability 
The essential components needed to assess a study for its measure of reproducibility are only 
available within the full text. To determine the ability of the general public to access the full text 
of each publication, we used the Open Access Button, Google, and PubMed. First, the DOI was 
used to search for each publication using the Open Access Button to determine if it was freely 
available to the public. If the Open Access Button returned no results or reported an error, we 
searched for the publication on Google and PubMed and analyzed the journal website to 
determine if the publication was available without a paywall.  
 
Statistical Analysis 
Descriptive statistics will be reported with 95% confidence intervals using Microsoft Excel. 
 
Results 
Of the 300 articles in our original sample, 2 were excluded due to not being in the English 
language and 4 were excluded because they could not be accessed. Of the 294 remaining articles, 
86 (29.25% [24.10% to 34.40%]) contained no empirical data, leaving 208 studies to be assessed 
for reproducibility. (Figure 1) The most common study design in our sample was cohort (58/294, 
19.73% [15.22% to 24.23%]), followed by cross-sectional (30/294, 10.20% [6.78% to 13.63%]), 
clinical trial (19/294, 6.46% [3.68% to 9.24%]), laboratory (19/294, 6.46% [3.68% to 9.24%]), 
case study (16/294, 5.44% [2.88% to 8.01%]) and meta-analysis (15/294, 5.01% [2.61% to 
7.59%]). All other study types made up less than 5% each of our sample. (Table 2) 
Among studies in our sample, 32 (16.58%) have been cited at least once by a meta-analysis, with 
10 (5.18%) being cited in multiple meta-analyses. Median 5-year impact factor of the journals 
the studies were published in was 2.478 (range .609-5.825). 
Studies in our sample had human subjects 59.52% of the time (175/294 [53.97% to 65.08%]), 
animal subjects 2.04% of the time (6/294 [0.44% to 3.64%]) and the remaining 38.44% (113/294 
[32.93% to 43.94%]) had neither human nor animal subjects. 
Indicators of Reproducibility  
Of the 294 articles in our sample, none claimed to be a replication study. In our sample, 72/294 
(24.49% [19.62% to 29.36%] were available via the Open Access Button, 2 (0.68% [0% to 
1.61%]) were accessible via other means, and 220 (74.83% [69.92% to 79.74%]) were only 
accessible through a paywall.  
 
Among studies with empiric data, 169 studies (89.42% [85.94% to 92.90%]) failed to provide a 
statement regarding the availability of their data. 20 (10.58% [7.10% to 14.06%]) provided a 
statement that data was available, with 13 providing data in a supplement, 1 hosting data on a 
third-party site and 6 stating that data is available upon request. Only 11 studies (5.82% [3.17% 
to 8.47%]) provided a statement on pre-registration, 9 of those were accessible. Among those 
that were accessible, 5 outlined the study’s hypothesis, 6 described the methods and 3 mentioned 
the plan for analysis. 168 (96.55% [94.49% to 98.62%]) studies failed to include a statement on 
materials availability, 5 (2.87% [0.98% to 4.76%]) reported that materials were available and 1 
stated that materials are not available. None of the studies in our sample provided a statement 
regarding analysis scripts or linked to accessible protocols. (Table 1) 
 
Conflict of Interest and Funding Statements 
294 articles in our sample were assessed for conflict of interest statements and funding source. 
76 (25.85% [20.90% to 30.80%]) contained no conflict of interest statement, 199 (67.69% 
[62.39% to 72.98%]) contained a statement reporting no financial conflict of interest and the 
remaining 19 (6.46% [3.68% to 9.24%]) contained a statement reporting one or more conflicts of 
interest. Among payment sources, mixed funding (38/294, 13.26% [9.43% to 17.10%]) was the 
most common, followed by public (25/294, 8.50% [5.34% to 11.66%]) and private (21/294, 
7.14% [4.23% to 10.06%]). 38 (12.93% [9.13% to 16.72%]) report no funding received and 159 
(54.08% [48.44% to 59.72%]) contain no statement regarding the source of funding. The 12 
remaining studies received funding from other sources. (Supplemental Table 1) 
 
Discussion 
Our study identified significant deficiencies in the reproducibility of research in Obstetrics and 
Gynecology. Unfortunately, our findings are not unique or unexpected. In a similar survey of 
social science research, Hardwicke et al. found that fewer than 10% of the studies in their sample 
provided a data availability statement, information about pre-registration, a materials statement, 
links to protocols or analysis scripts.​9​ In addition, they found that less than half of the studies in 
their sample were available through Open Access and the majority did not include a statement on 
the source of their funding. All of the above results match with what we found in our survey.  
A major area of concern from our sample is the lack of data availability. In bioinformatics and 
biostatistics, Ioannidis et al. attempted to reproduce 16 studies and found that 2 were 
reproducible, 6 were partially reproducible and 10 were not reproducible, with the main reason 
for failure being lack of data availability.​14​ Other studies have found that many journals do not 
have a policy regarding data availability.​15,16​ While journals that do require data availability have 
increased data availability, sub-optimal adherence continues to be an issue.​17​ We found that 
fewer than 11% of studies in our sample provided a data availability statement. While it would 
be ideal for all studies to provide their data in a supplement or to be hosted on an accessible 
third-party site, authors should take it upon themselves to at least make data available upon 
reasonable request. Inability to access raw data can lead to inaccuracies and misleading results in 
the medical literature.​18 
Compounding the lack of data availability is the lack of data accessibility. Our sample found that 
only one in four articles was available through Open Access or with our academic privilege. If 
investigators are unable to access relevant research to their topic, it is unreasonable to expect that 
research to be reproduced. Indeed we found no articles that claimed to replications of previous 
studies. A survey by Baker et al. found that while a majority of researchers had failed to 
reproduce a study, few researchers attempted to publish their findings.​19​ The same survey 
reported that the most common reasons for poor reproducibility are selective reporting, pressure 
to publish, poor analysis, low statistical power and the research not being well-replicated in the 
original lab. 
In our data set, no studies provided links to protocols or analysis scripts and only 6 contained a 
materials statement. Protocols, materials statements and analysis scripts are three of the most 
critical elements of reproducibility in a study. Protocols provide a painstakingly thorough guide 
to how each step of the study was performed, containing details that may not be relevant to most 
of the individuals reading the methods section.​20​ Analysis scripts provide explicit details on how 
the analysis was conducted, while materials statements allow future researchers to replicate the 
experiment using the same tools, questionnaires, forms, etc.​21​ Simply requiring that protocols, 
analysis scripts and materials statements are provided in supplement or on a third-party website 
is an easy way for journal editors to improve the reproducibility of the studies they publish. 
Only 11 studies in our sample provided a statement on pre-registration. Nosek et al. underscores 
the importance of pre-registration by distinguishing between hypothesis-generating research and 
hypothesis-confirming research, noting that the two should not occur simultaneously.​22​ Crucially, 
Nosek states that presenting post hoc explanations as predictions decreases reproducibility and 
falsely inflates the authors conviction in the strength of their evidence. This is to say nothing of 
p-hacking or selective outcome reporting, both of which can be easily identified in pre-registered 
studies.​23,24​ Over the last several decades, the Food and Drug Administration (FDA) and the 
World Health Organization (WHO) have passed legislation to increase transparency and 
reproducibility in clinical trials by creating the Clinicaltrials.gov and the International Clinical 
Trials Registry Platform. ​25,26​ Since 2007, the United States has mandated the pre-registration of 
clinical trials through the FDA Amendments Act.​27​ While not a total success, clinical trial 
registration has improved significantly.​28,29​ While government policy could be an effective way 
to encourage the pre-registration of all empiric research, at this point it is up to authors to 
pre-register their studies and journal editors to implement policies that every study be 
pre-registered. 
Among the 294 studies in our sample, only 218 contained a statement regarding financial 
conflict of interest. Once again, this is not a unique issue in research in Obstetrics and 
Gynecology. Cross-sectional studies in several fields have shown significant deficits in conflict 
of interest reporting, where 100% disclosure is the only acceptable outcome.​30–33​ Thompson et al. 
found that among abstract authors in Obstetrics and Gynecology, 62% had undisclosed financial 
conflicts of interest, with the majority of those (68%) being relevant to the topic of the abstract.​34 
Financial conflicts of interest are a rampant problem in scientific literature, and it is clear that 
self-reporting is not sufficient as a method to fix the problem.​35–37 
To help solve the problems of poorly reproducible research, The Open Science Framework 
(OSF) was launched by the Center for Open Science.​38​ One of the ways they set out to 
accomplish this was to host research pre-registration free of charge. Additionally, in 2015, the 
OSF published the Transparency and Openness Promotion (TOP) guidelines which outlined 8 
modular standards across 3 tiers to improve transparency, cooperation and reproducibility.​39 
Separately, McIntosh et al. developed Repeat, a checklist for authors that emphasizes 5 areas of 
reproducibility, including many of the same indicators that our study assessed for.​40​ Reporting 
guidelines are another tool that some journals require to ensure that data is reported completely 
and accurately.​41–43​ More regular use of any of the above tools would almost certainly lead to 
increased reproducibility. 
Our study contains several important limitations. First is our sample size compared to the bulk of 
research in Obstetrics and Gynecology. We felt that 300 studies would be a suitably robust 
sample to give us a good snapshot of the reproducibility of literature in the field, but we would 
be naive to believe that our sample was so large that it could be definitively labeled as 
“representative.” Second, we did not individually interrogate individual authors for data 
availability, analysis scripts or protocols. Research has already been done on the success rates of 
author inquiry and we felt it wasn’t necessary to include in our analysis.​44,45 
Conclusion 
Research in the field of Obstetrics and Gynecology rates poorly on indicators of reproducibility. 
Additionally, there are an unacceptable number of studies published without financial conflict of 
interest disclosures. We call upon authors to take steps to increase reproducibility including 
using reporting guidelines, the Repeat checklist and by pre-registering their studies. Additionally 
we recommend professional societies and journal editors to adopt more stringent policies 
regarding data and protocol availability as well as conflicts of interest statements. 
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Figure 1. Prisma Diagram for included and excluded studies 
 
 
 
Table 1:​ Reproducibility related characteristics. Variable numbers (N) are dependent upon study design. 
Full detailed protocol pertaining to our measured variables is available online (​https://osf.io/x24n3/​) 
 
Indicators of Reproducibility Included in Present 
Study 
Significance of measure variable for 
transparency and reproducibility. 
Publications 
All 
(N=300) 
Publication accessibility (Is the 
publication open access to the general 
public or accessible through a 
paywall?) 
 
The general public’s ability to access scientific 
research may increase transparency of results 
and improve the ability for others to critically 
assess studies, potentially resulting in more 
replication studies 
Funding 
Included 
studies 
(N=294) 
Funding statement (Does the 
publication state their funding 
sources?) 
 
Explicitly providing source of funding may 
help mitigate bias and potential conflicts of 
interest  
Conflict of Interest 
Included 
studies 
(N=294) 
Conflict of interest statement (Does the 
publication state whether or not the 
authors had a conflict of interest?)  
Explicitly providing conflicts of interest may 
allow for full disclosure of factors that may 
promote bias in the study design or outcomes  
Publication Citations 
Empirical 
studies† 
(N=208) 
Citations by a systematic 
review/meta-analysis (Has the 
publication been cited by any type of 
data synthesis publication, and if so, 
was it explicitly excluded?)  
Systematic reviews and meta-analyses evaluate 
and compare existing literature to assess for 
patterns, strengths, and weaknesses of studies 
regarding a particular field or topic  
Analysis Scripts 
Empirical 
studies‡ 
(N=189) 
Availability statement (Does the 
publication state whether or not the 
analysis scripts are available?) 
 
Access to the analysis script helps promote 
credibility by ensuring raw data can be analyzed 
in the same way to get the same 
 
Method of availability (Ex: Are the 
analysis scripts available upon request 
or in a supplement?) 
Accessibility (Can you view, 
download, or otherwise access the 
analysis scripts?) 
Materials 
Empirical 
studies¶ 
(N=174) 
Availability statement (Does the 
publication state whether or not the 
materials are available?) 
 
Access to the study materials helps promote 
credibility by ensuring the study can be 
conducted in the same way, using the same 
materials  
Method of availability (Ex: Are the 
materials available upon request or in a 
supplement?) 
Accessibility (Can you view, 
download, or otherwise access the 
materials?) 
Pre-registration 
Empirical 
studies‡ 
(N=189) 
Availability statement (Does the 
publication state whether or not it was 
pre-registered?) 
 
Pre-registering studies may decrease potential 
bias and increase the overall credibility of a 
study 
Method of availability (Where was the 
publication pre-registered?) 
Accessibility (Can you view or 
otherwise access the registration?) 
Components (What components of the 
publication were pre-registered?) 
Protocols 
Empirical 
studies‡ 
(N=189) 
Availability statement (Does the 
publication state whether or not a 
protocol is available?)  
Access to detailed protocols allows for 
replication of studies with the same 
methodology, increasing both the credibility of a 
study and chance of replication  Components (What components are 
available in the protocol?) 
Raw Data 
Empirical 
studies‡ 
(N=189) 
Availability statement (Does the 
publication state whether or not the raw 
data are available?) 
 
Access to raw data can help improve the 
replication ability of a study and minimize 
potential for bias and issues of validity and 
reliability 
Method of availability (Ex: Are the raw 
data available upon request or in a 
supplement?) 
Accessibility (Can you view, 
download, or otherwise access the raw 
data?) 
Components (Are all the necessary raw 
data to reproduce the study available?) 
Clarity (Are the raw data documented 
clearly?) 
† 'Empirical studies’ are publications that include empirical data such as: clinical trial, cohort, case 
series, case reports, case-control, secondary analysis, chart review, commentaries (with data analysis), 
laboratory, and cross-sectional designs. 
‡ Empirical studies determined to be case reports or case series were excluded in regards to 
reproducibility related questions (materials, data, protocol, and registration were excluded) as 
recommended by Wallach et al. (cite) 
¶ Empirical studies determined to be either case reports, case series, commentaries with analysis, 
meta-analysis or systematic review were excluded as they did not provide materials to fit the category. 
 
 
Table 2. ​Characteristics of Included Publications  
 
Table 2: Characteristics of Included Publications 
Characteristics Variables 
 N (%) 95% CI 
Funding 
N=294 
University 6 (2.04) 0.44-3.64% 
Hospital 2 (0.68) 0-1.61% 
Public 25 (8.50) 5.35-11.66% 
Private/Industry 21 (7.14) 4.23-10.06% 
Non-Profit 4 (1.36) 0.05-2.67% 
Mixed 39 (13.27) 13.54-14.04% 
No Statement Listed 159 (54.08) 48.44-59.72% 
No Funding Received 38 (12.93) 9.13-16.72% 
 
Type of Study 
N=294 
No Empirical Data 86 (29.25) 24.10-34.40% 
Meta-Analysis 15 (5.10) 2.61-7.59% 
Cost-Effectiveness 6 (2.04) 0.44-3.64% 
Clinical Trial 19 (6.46) 3.68-9.24% 
Case Study 16 (5.44) 2.88-8.01% 
Case Series 3 (1.02) 0-2.16% 
Cohort 58 (19.73) 15.22-24.23% 
Chart Review 10 (3.40) 1.35-5.45 
Case Control 13 (4.42) 2.10-6.75% 
Survey 8 (2.72) 0.88-4.56% 
Cross-Sectional 30 (10.20) 6.78-13.63% 
Secondary Analysis 10 (3.40) 1.35-5.45) 
Laboratory 19 (6.46) 3.68-9.24% 
Multiple Study Types 1 (0.34) 0-1.00% 
    
5 Year Impact 
Factor 
N=268 
Median 2.478 - 
1st Quartile 1.741 - 
3rd Quartile 3.284 - 
Interquartile Range 1.741-3.284 - 
 
